Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.59 |
| ▸ | BUB1 | O43683 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706107 | 0.92 | PDE4B (0.70) | PDE4BSMN1; SMN2GSK3B | |
| SCHEMBL4708777 | 0.91 | PDE4B (0.62) | PDE4BBUB1SMN1; SMN2KMT2A | |
| SCHEMBL3033125 | 0.90 | PDE4B (0.48) | PDE4BBUB1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL4682246 | 0.90 | PDE4B (0.47) | PDE4BBUB1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL1653053 | 0.90 | PDE4B (0.47) | PDE4BBUB1SMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL1652540 | 0.90 | PDE4B (0.56) | PDE4BCYP1A1CYP1A2CYP1B1KMT2A | |
| SCHEMBL3033443 | 0.88 | PDE4B (0.59) | PDE4BBUB1SMN1; SMN2KMT2A | |
| SCHEMBL4705837 | 0.88 | PDE4B (0.56) | PDE4BSMN1; SMN2 | |
| SCHEMBL4674510 | 0.87 | PDE4B (0.69) | PDE4BBUB1SMN1; SMN2 | |
| SCHEMBL3033419 | 0.87 | PDE4B (0.59) | PDE4BBUB1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4679154-B2 | — | — | 2011-04-27 | — | — | JP | claimed |
| US-20100204241-A9 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2010-08-12 | — | — | US | claimed |
| US-20090111819-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2009-04-30 | — | — | US | claimed |
| US-7491722-B2 | Pyridazin-3(2H)-one derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-17 | — | — | US | claimed |
| EP-1575926-B1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | ALMIRALL LAB (ES) | 2008-03-05 | — | — | EP | claimed |
| US-20060173008-A1 | New pyridazin-3(2h)-one derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-08-03 | — | — | US | claimed |
| JP-2006515302-A | — | — | 2006-05-25 | — | — | JP | claimed |
| EP-1575926-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2005-09-21 | — | — | EP | claimed |
| WO-2004058729-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | ALMIRALL PRODESFARMA SA (ES) | 2004-07-15 | — | — | WO | claimed |
| US-20100204241-A9 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2010-08-12 | — | — | US | disclosed |
| US-20090111819-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2009-04-30 | — | — | US | disclosed |
| US-7491722-B2 | Pyridazin-3(2H)-one derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-17 | — | — | US | disclosed |
| EP-1575926-B1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | ALMIRALL LAB (ES) | 2008-03-05 | — | — | EP | disclosed |
| US-20060173008-A1 | New pyridazin-3(2h)-one derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111819-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | PDE4A, PDE3A, PDE3B | PDE4B 5/4885BUB1 4122/4885SMN1; SMN2 3744/4885 |
| US-20060173008-A1 | New pyridazin-3(2h)-one derivatives | PDE3A, PDE4A, PDE3B | PDE4B 4/4885BUB1 4333/4885SMN1; SMN2 3892/4885 |
| US-20100204241-A9 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | PDE4A, PDE3A, PDE3B | PDE4B 5/4885BUB1 4122/4885SMN1; SMN2 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.